Gbola Amusa

Dr. Gbola Amusa is Partner and Chief Scientific Officer of Chardan. Working within the Investment Banking Division, he is responsible for advising disruptive healthcare companies on capital formation strategies, M&A, and other transactions. Dr. Amusa joined Chardan at the end of 2014 to focus on identifying companies that will generate exceptionally high long-term investment returns from creating and sharing in real value for society. While in Chardan's Equity Research Department from 2014 through early July 2021, Dr. Amusa’s coverage, top picks, and counter-consensus calls were all associated with the exceptional alpha generation, with Dr. Amusa, for example, ranked #2 out of over 6,000 Wall Street analysts in 2019 for his stock-picking performance in a study by TipRanks.

Dr. Amusa was previously Managing Director, Head of European Pharma Research, and Global Pharma & Biotech Coordinator at UBS, where he oversaw 25 analysts, and ultimately finished as the #1 ranked European pharma analyst in the Institutional Investor (II) Survey. Prior to UBS, Dr. Amusa was a Senior Research Analyst and Head of European Pharma research at Sanford Bernstein. He started his career in finance at Goldman Sachs as an Associate in the Healthcare Investment Banking Group, where he worked on large transactions including the Amgen/Immunex merger. Additionally, Dr. Amusa was previously a Healthcare Finance & Strategy Consultant working with governments, companies, leading foundations, and think tanks. Dr. Amusa’s views on healthcare have been cited by socially responsible investing (SRI), ESG and sustainability organizations like FSG/Shared Value Initiative, GMI Ratings and the

ATM Index.

Dr. Amusa earned his BSE with honors in biomedical engineering from Duke University, an MD from Washington University Medical School, and his MBA with honors from the University of Chicago, Booth School of Business.